We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

End in sight

30 March 2010 By Robert Cyran

After Japan’s Astellas went hostile for the $3.5 bln U.S. biotech, many expected a bidding war to break out. OSI is trying to attract rival suitors, but has now opened its books to Astellas. A sweetened bid, around current market values, would probably seal the deal.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)